

# Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective

Athena Kritharis,<sup>1</sup> Hanny Al-Samkari<sup>2</sup> and David J Kuter<sup>2</sup>

<sup>1</sup>Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ and <sup>2</sup>Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.193003

Received: April 4, 2018.

Accepted: May 14, 2018.

Pre-published: May 24, 2018.

Correspondence: hal-samkari@mgh.harvard.edu

---

**Supplemental Table.** Active and recruiting clinical trials in hereditary hemorrhagic telangiectasia.

<b>Trial Number (clinicaltrials.gov)</b>	<b>Locations</b>	<b>Trial Name</b>
NCT01402531	U.S.	Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT03227263	France	BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia
NCT01397695	U.S.	Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT01752049	Canada U.S.	Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
NCT01406639	U.S.	Ranibizumab for the Management of Recurrent Nosebleeds in Patients with Hereditary Hemorrhagic Telangiectasia
NCT02638012	Canada	Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With HHT
NCT02874326	Netherlands	Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber (ROW)
NCT02389959	U.S.	Intranasal Bevacizumab for HHT-Related Epistaxis
NCT02204371	U.S. Canada	Evaluation of Pazopanib on Bleeding in Subjects with Hereditary Hemorrhagic Telangiectasia